Stc.unm

Unm Rainforest Innovations

Other

University of Michigan

Sanford-burnham Medical Research Institute

Peter C Simons

Angela Wandinger-Ness

Tione Buranda

Larry A Sklar

Eric R Prossnitz

Jacob Ongudi Agola

Soumik BasuRay

Scarlett Swanson

Virginie Bondu

Daniel F Cimino

John C Reed

Dayong Zhai

Anna Waller

Mathewos Z Tessema

Sean Biggs

Alex T Key

Mei Shi

Stephen Young

In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infection-associated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.

Activated GTPase-based assays and kits for the diagnosis of sepsis and other infections

The present invention is directed to the discovery that RapI-GTP, Rac1-GTP and Flt3-L can be used as Biomarkers for the early detection of sepsis in patients suspected of a bacterial infection which presents as sepsis or is likely to produce sepsis. In particular, the present invention is directed to methods, assays and kits which may be used to distinguish sepsis (infection) from systematic inflammatory response caused by sterile inflammation in trauma patients. The method may be used to diagnose bacteria infection and/or sepsis and monitor therapy of a patient to allow modification of treatment and/or cessation of treatment.

Rap1-Gtp, Rac1-GTP and FMS-like tyrosine kinase 3 ligand (FLT3-L) as biomarkers for early detection of sepsis

The present invention relates generally to glutathione derivatized beads which are adapted for use in conjunction with glutathione-S-transferase fusion proteins (generally, GST fusion proteins, which contain a fluorescent label such as fluorescent green protein) for use in flow cytometry. The present invention also relates to methods for detecting and/or quantifying interactions between a GST fusion protein and their binding partners, in particular, labeled binding partners such as fluorescently labeled binding partners. By creating glutathione beads with an appropriate high or increased site density, disadvantages often associated with low affinity systems and quick off-rates in solution may be resolved to provide a workable system and method. Methods of identifying potential agonists, antagonists and regulator compounds of proteins fused to GST from libraries of compounds represents another aspect of the present invention.

Glutathione beads and GST fusion proteins

The present invention relates generally to molecular assemblies, more particularly to an assay for the detection of G-protein coupled receptor (GPCR) molecular assemblies and bead-based detection of ligand-GPCR complexes and to methods for identifying compounds as agonists, partial agonists or antagonists of the binding of G-protein coupled receptors to G-protein and for use of these compounds in the treatment of conditions or disease states in a mammalian subject or patient, including humans, where G-protein coupled receptor binding to G-protein is implicated.

Multiplex analysis for high throughput discrimination of GPCR agonists and antagonists

The present invention provides a general approach for G protein coupled receptors that may be used to define agonists and antagonists, and the specificity of receptor coupling to G protein subunits. Methods of the present invention use small volumes (microliters) and are compatible with high throughput flow cytometry. When assays of the present invention are multiplexed, the specificity of the interactions of a receptor with many G proteins may be determined simultaneously.

Bead-based detection of ligand-GPCR-G protein complexes

Growing community of inventors

Albuquerque, NM, United States of America

Peter C Simons